Omeros Corp. (OMER) fundamentals score
Omeros Corporation is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.2 out of 10, Weak long-term fundamentals
- Growth: 3.8/10
- Profitability: 2.4/10
- Financial health: 2.7/10
- Earnings quality: 8.1/10
- Valuation: 5.8/10
Scores are calculated from Omeros Corp.’s SEC filings, using the 12 months through 2021-09. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10